FDA Approves Amgen ' s Repatha (evolocumab) to Prevent Heart Attack and Stroke

THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha (evolocumab) as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news